Literature DB >> 6102579

Inotropic drugs in acute circulatory failure.

P Herbert, J Tinker.   

Abstract

The use of inotropic drugs in patients requiring acute circulatory support is reviewed. A knowledge of their various peripheral effects is essential if the appropriate drug is to be used. The place or pressor amines, digitalis, salbutamol and glucagon in the treatment of patients with poor tissue perfusion is limited. Of the catecholamines, adrenaline causes excessive renal vasoconstriction and peripheral gangrene, noradrenaline increase myocardial work and diminishes peripheral perfusion and isoprenaline distributes blood away from the vital organs, namely: brain, kidneys, heart and mesentery. Dopamine is a useful agent as it enhances renal blood flow in low doses and is not excessively chronotropic. Dobutamine has not yet been shown to have significant advantages over other inotropes and requires further examination.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6102579     DOI: 10.1007/bf01683355

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  114 in total

1.  HEMODYNAMIC EFFECTS OF PRESSOR AGENTS IN SEPTIC AND MYOCARDIAL INFARCTION SHOCK.

Authors:  H SMULYAN; R P CUDDY; R H EICH
Journal:  JAMA       Date:  1964-10-19       Impact factor: 56.272

2.  Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs.

Authors:  S F Vatner; R J McRitchie; E Braunwald
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

3.  Principle defects which account for shock following acute myocardial infarction in man: implications for treatment.

Authors:  H Mueller; S M Ayres; W J Grace
Journal:  Crit Care Med       Date:  1973 Jan-Feb       Impact factor: 7.598

4.  Comparison of the peak inotropic effects of a catecholamine and a digitalis glycoside in the intact canine heart.

Authors:  G D Beiser; S E Epstein; R E Goldstein; M Stampfer; E Braunwald
Journal:  Circulation       Date:  1970-11       Impact factor: 29.690

5.  Dopamine in open-heart surgery for congenital heart disease.

Authors:  W Daenen; M de Leval; J Stark
Journal:  Proc R Soc Med       Date:  1977

6.  Coronary vasodilatation produced by dopamine after adrenergic blockade.

Authors:  D M Schuelke; A L Mark; P G Schmid; J W Eckstein
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

7.  Hemodynamic studies in cardiogenic shock. Treatment with isoproterenol and metaraminol.

Authors:  H J Smith; A Oriol; J Morch; M McGregor
Journal:  Circulation       Date:  1967-06       Impact factor: 29.690

8.  Cardiac norepinephrine stores and the contractile state of heart muscle.

Authors:  J F Spann; E H Sonnenblick; T Cooper; C A Chidsey; V L Willman; E Braunwald
Journal:  Circ Res       Date:  1966-08       Impact factor: 17.367

9.  Effect of 1-epinephrine on the coronary circulation in human subjects with and without coronary artery disease.

Authors:  J M Sullivan; R Gorlin
Journal:  Circ Res       Date:  1967-12       Impact factor: 17.367

10.  Effects of dobutamine in patients with acute myocardial infarction.

Authors:  T A Gillespie; H D Ambos; B E Sobel; R Roberts
Journal:  Am J Cardiol       Date:  1977-04       Impact factor: 2.778

View more
  4 in total

Review 1.  Vasodilators in acute circulatory failure.

Authors:  C Blakeley; J Tinker
Journal:  Intensive Care Med       Date:  1983       Impact factor: 17.440

Review 2.  Myocardial infarction (ST-elevation).

Authors:  Abel P Wakai
Journal:  BMJ Clin Evid       Date:  2011-01-07

Review 3.  Myocardial infarction (ST-elevation).

Authors:  Abel P Wakai
Journal:  BMJ Clin Evid       Date:  2009-01-09

Review 4.  Clinical pharmacological and therapeutic considerations in general intensive care. A review.

Authors:  M L Farina; M Bonati; G Iapichino; A Pesenti; F Procaccio; L Boselli; M Langer; A Graziina; G Tognoni
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.